LFCR vs TLSI
LFCR: Lifecore Biomedical is a specialized CDMO focused on complex sterile injectable fill-finish and manufacturing services for the pharmaceutical industry. TLSI: TriSalus is a medical technology company integrating proprietary pressure-enabled drug delivery devices with immunotherapeutics to improve outcomes for patients with liver and pancreatic cancer.
Side-by-side fundamentals
| Metric | LFCR | TLSI | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $4.58 | $4.24 | |
| Market cap as of 2026-07-23 | $174M | $267M | |
| PEG as of 2026-07-23 | n/a | -0.12 | |
| Net margin as of 2026-07-23 | -26.5% | -60.9% | LFCR higher |
| Gross margin as of 2026-07-23 | +30.0% | +85.1% | TLSI higher |
| Operating margin as of 2026-07-23 | -1.9% | -62.5% | LFCR higher |
| ROE as of 2026-07-23 | -126.8% | +12.0% | TLSI higher |
| ROA as of 2026-07-23 | -18.9% | -59.4% | LFCR higher |
| Debt / equity as of 2026-07-23 | 7.16 | 2.58 | TLSI lower |
| Revenue growth (YoY) as of 2026-07-23 | +27.6% | +39.6% | TLSI higher |
| Revenue CAGR (3y) SEC XBRL | +5.3% | +53.9% | TLSI higher |
| Beta as of 2026-07-23 | 1.12 | 0.40 | |
| 1-year return as of 2026-07-22 close | -38.4% | -5.0% | TLSI higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.